Foon K A, Gale R P
Department of Internal Medicine, University of Michigan, Ann Arbor.
Blood Rev. 1987 Jun;1(2):77-88. doi: 10.1016/0268-960x(87)90001-4.
Important insights into lymphocyte differentiation and the cellular origins of lymphoma and lymphoid leukemia have been gained through the use of monoclonal antibodies that define cell surface antigens and molecular probes that identify immunoglobulin and T cell receptor genes. Results of these studies have been combined with markers such as surface membrane and cytoplasmic immunoglobulin on B lymphocytes, sheep erythrocyte receptors on T lymphocytes, and cytochemical stains. Utilising all of the above markers, it is now clear that acute lymphoblastic leukemia (ALL) is heterogeneous. Furthermore, monoclonal antibodies that identify B cells such as the anti-B1 and anti-B4 antibodies in combination with studies of immunoglobulin gene rearrangement have demonstrated that virtually all cases of non-T-ALL involve B lymphocytes. At least six distinct subgroups of non-T-ALL can now be identified. T-ALL is subdivided by the anti-Leu-9, anti-Leu-1, and additional antibodies that separate T lymphocyte subsets into three primary subgroups. Monoclonal antibodies are also useful in the subclassification of non-Hodgkin's lymphoma, and certain distinct markers can be correlated with morphologic classification.
通过使用定义细胞表面抗原的单克隆抗体和识别免疫球蛋白及T细胞受体基因的分子探针，人们对淋巴细胞分化以及淋巴瘤和淋巴样白血病的细胞起源有了重要认识。这些研究结果已与诸如B淋巴细胞上的表面膜和细胞质免疫球蛋白、T淋巴细胞上的绵羊红细胞受体以及细胞化学染色等标志物相结合。利用上述所有标志物，现已明确急性淋巴细胞白血病（ALL）具有异质性。此外，识别B细胞的单克隆抗体，如抗B1和抗B4抗体，与免疫球蛋白基因重排研究相结合，已证明几乎所有非T-ALL病例都涉及B淋巴细胞。现在至少可以识别出非T-ALL的六个不同亚组。T-ALL通过抗Leu-9、抗Leu-1以及将T淋巴细胞亚群分为三个主要亚组的其他抗体进行细分。单克隆抗体在非霍奇金淋巴瘤的亚分类中也很有用，某些独特的标志物可与形态学分类相关联。
